Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
"This book describes the state of EGFR antagonist development and treatment modalities.... This will be of interest to those in academic research studying EGFR signaling and/or cancer. ... This is an excellent reference for those focused on a particular aspect of EGFR signaling who are looking for a concise review. This is a timely review of an increasingly complex area of study." (James P. Luyendyk, Doody's Review Service, January, 2009)
"This book bridges the basic and clinical progress in EGFR network in cancer therapy over 40 years of EGFR research. Due to the contributors' basic science and clinical backgrounds, the book is ... best suited for basic scientists, translational scientists, and oncologists who engage in EGFR associated research and clinical therapy at various levels. The book provides a comprehensive EGFR resource for researchers not only in basic biological fields but also in preclinical and clinical therapy ... ." (Guolin Zhang and Eric B. Haura, Cancer Control, Vol. 16 (4), October, 2009)
"This book is a collection of articles from different authors organized into two sections. ... a good and useful book for any medicinal chemist working in this field ... . all chapters are well written, clear, and rather agreeable to read. ... easily understood by even an inexperienced reader. ... a useful introduction to the role of EGFR signaling networks in a large number of tumors for novice researchers, but it could also be considered in some way a reference text for more experienced ones." (Adriano Martinelli, ChemBioChem, Vol. 5, 2010)